Ionis Pharmaceuticals Inc
$
64.72
-2.42 (-3.6%)
| Volume: | 2,588,017 | Avg Vol (1m): | 1,384,580 |
| Market Cap $: | 9.08 Bil | Enterprise Value $: | 7.68 Bil |
| P/E (TTM): | 25.83 | P/B: | 7.58 |
| Earnings Power Value | -5.01 |
| Net Current Asset Value | 5.27 |
| Tangible Book | 8.35 |
| Projected FCF | 20.4 |
| Median P/S Value | 69.01 |
| Graham Number | 21.72 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 3.37 |
Cash-To-Debt ranked
lower than
66.79%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
IONS:
3.37
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.24, Med: 1.52, Max: 11.14
Current: 3.37
|
| Equity-to-Asset | 0.43 |
Equity-to-Asset ranked
lower than
84.01%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
IONS:
0.43
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.85, Med: 0.35, Max: 0.8
Current: 0.43
|
| Debt-to-Equity | 0.55 |
Debt-to-Equity ranked
lower than
81.60%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
IONS:
0.55
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -19.36, Med: 0.9, Max: 742.15
Current: 0.55
|
| Debt-to-EBITDA | 5.80 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
IONS:
5.8
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -61.12, Med: -8.88, Max: 16.72
Current: 5.8
|
| Interest Coverage | 1.40 |
Interest Coverage ranked
lower than
100.00%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
IONS:
1.4
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 0.69, Med: 0.69, Max: 1.4
Current: 1.4
|
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 4.76 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -1.26 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 0%
WACC 12.01%
| ||
Profitability & Growth : 6/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 8.43 |
Operating Margin ranked
higher than
67.05%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
IONS:
8.43
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -71.76, Med: -24.68, Max: 8.43
Current: 8.43
|
| Net Margin % | 47.79 |
Net Margin ranked
higher than
68.94%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
IONS:
47.79
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -85.58, Med: -24.66, Max: 127.52
Current: 47.79
|
| ROE % | 45.74 |
ROE ranked
higher than
70.98%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
IONS:
45.74
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -40.77, Med: -22.23, Max: 86.43
Current: 45.74
|
| ROA % | 15.91 |
ROA ranked
higher than
76.48%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
IONS:
15.91
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -16.38, Med: -7.6, Max: 25.19
Current: 15.91
|
| ROC (Joel Greenblatt) % | 78.62 |
ROC (Joel Greenblatt) ranked
higher than
71.81%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
IONS:
78.62
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -152.05, Med: -55.1, Max: 78.62
Current: 78.62
|
| 3-Year Total Revenue Growth Rate | 28.30 |
3-Year Revenue Growth Rate ranked
higher than
82.49%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
IONS:
23.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -39.5, Med: 7.2, Max: 83.7
Current: 23.6
|
| 3-Year Total EBITDA Growth Rate | 22.80 |
3-Year EBITDA Growth Rate ranked
lower than
100.00%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
IONS:
25.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 2.45, Max: 49.7
Current: 25.6
|
» IONS's 30-Y Financials
Financials (Next Earnings Date: 2019-08-07)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:IONS
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | OCSE:GEN NAS:SGEN NAS:ALNY NAS:SRPT NAS:SAGE HKSE:01177 NAS:MRNA HKSE:02269 NAS:BLUE SZSE:000661 OCSE:NZYM B NAS:JAZZ NAS:TECH HKSE:06160 NAS:NBIX SZSE:002252 TSE:4587 NAS:AMRN XAMS:GLPG NAS:EXEL |
| Traded in other countries | ISI.Germany 0JDI.UK |
| Address | 2855 Gazelle Court, Carlsbad, CA, USA, 92010 |
| Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline consists treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 25.83 |
PE Ratio ranked
lower than
100.00%
of
248
companies
in the
Biotechnology
industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
IONS:
25.83
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 5.56, Med: 31.29, Max: 1138.6
Current: 25.83
|
| PE Ratio without NRI | 25.83 |
PE without NRI ranked
lower than
100.00%
of
243
companies
in the
Biotechnology
industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
IONS:
25.83
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 7.18, Med: 161.25, Max: 1138.6
Current: 25.83
|
| Price-to-Owner-Earnings | 11.01 |
Price-to-Owner-Earnings ranked
higher than
78.62%
of
145
companies
in the
Biotechnology
industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
IONS:
11.01
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 5.9, Med: 16.77, Max: 361.48
Current: 11.01
|
| PB Ratio | 7.58 |
PB Ratio ranked
lower than
79.31%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
IONS:
7.58
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 3, Med: 9.81, Max: 65.21
Current: 7.58
|
| PS Ratio | 11.94 |
PS Ratio ranked
higher than
51.10%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
IONS:
11.94
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 6.59, Med: 12.75, Max: 44.19
Current: 11.94
|
| Price-to-Free-Cash-Flow | 12.57 |
Price-to-Free-Cash-Flow ranked
higher than
84.21%
of
152
companies
in the
Biotechnology
industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
IONS:
12.57
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 3.69, Med: 48.48, Max: 1346.3
Current: 12.57
|
| Price-to-Operating-Cash-Flow | 12.23 |
Price-to-Operating-Cash-Flow ranked
higher than
84.29%
of
210
companies
in the
Biotechnology
industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
IONS:
12.23
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.55, Med: 50.95, Max: 1474.69
Current: 12.23
|
| EV-to-EBIT | 75.23 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
IONS:
75.23
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -699.2, Med: -21.7, Max: 1026.9
Current: 75.23
|
| EV-to-EBITDA | 66.60 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
IONS:
66.6
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -3251.2, Med: -21.85, Max: 1026.9
Current: 66.6
|
| EV-to-Revenue | 10.21 |
EV-to-Revenue ranked
higher than
57.07%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
IONS:
10.21
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 3.7, Med: 11.4, Max: 43.4
Current: 10.21
|
| Current Ratio | 9.40 |
Current Ratio ranked
higher than
71.60%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
IONS:
9.4
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.27, Med: 5.24, Max: 9.89
Current: 9.4
|
| Quick Ratio | 9.36 |
Quick Ratio ranked
higher than
71.97%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
IONS:
9.36
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.27, Med: 5.06, Max: 9.89
Current: 9.36
|
| Days Inventory | 1.00 |
Days Inventory ranked
lower than
100.00%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
IONS:
1
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 1, Med: 1861.5, Max: 1861.5
Current: 1
|
| Days Payable | 2.00 |
Days Payable ranked
lower than
100.00%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
IONS:
2
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 2, Med: 5747.75, Max: 5747.75
Current: 2
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -3.70 |
3-Year Share Buyback Rate ranked
higher than
87.75%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
IONS:
-3.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -31.9, Med: -7.9, Max: -0.8
Current: -3.7
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 7.75 |
Price-to-Tangible-Book ranked
lower than
73.60%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
IONS:
7.75
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.71, Med: 8.5, Max: 191.18
Current: 7.75
|
| Price-to-Projected-FCF | 3.17 |
Price-to-Intrinsic-Value-Projected-FCF ranked
higher than
50.26%
of
193
companies
in the
Biotechnology
industry.
Industry Max: 117, Med: 3.12, Min: 0.09
IONS:
3.17
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.67, Med: 15.82, Max: 564.67
Current: 3.17
|
| Price-to-Median-PS-Value | 0.94 |
Price-to-Median-PS-Value ranked
higher than
57.67%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
IONS:
0.94
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 0.95, Max: 5.12
Current: 0.94
|
| Price-to-Graham-Number | 2.98 |
Price-to-Graham-Number ranked
lower than
100.00%
of
200
companies
in the
Biotechnology
industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
IONS:
2.98
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 2.97, Med: 15.05, Max: 32.88
Current: 2.98
|
| Earnings Yield (Joel Greenblatt) % | 1.32 |
Earnings Yield (Greenblatt) ranked
higher than
73.54%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
IONS:
1.32
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -12.8, Med: -1.3, Max: 2
Current: 1.32
|
More Statistics
| Revenue (TTM) (Mil) $ | 752.47 |
| EPS (TTM) $ | 2.51 |
| Beta | 1.82 |
| Volatility % | 37.44 |
| 52-Week Range $ | 40.91 - 86.58 |
| Shares Outstanding (Mil) | 140.32 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |